Market Currents
BG Medicine (BGMD) rockets 24% after saying it has received the EU's CE mark for the first...
-
Thursday, January 3, 8:28 AM ETBG Medicine (BGMD) rockets 24% after saying it has received the EU's CE mark for the first automated version of the company's Galectin-3 blood test for improving the management of heart conditions. BG is working with four partners to commercialize the test, including Abbott Labs (ABT) and Siemens (SI). The EU approval comes just a week after SA author Robert Fabian called BG Medicine a "hidden gem." (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
